ClinicalTrials.Veeva
Menu

Find clinical trials for Acute Myeloid Leukemia (AML) in Montréal, QC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Acute Myeloid Leukemia
Leukemia
Myeloid Leukemia
Myelodysplastic Syndromes
Preleukemia
Chronic Myelomonocytic Leukemia
Syndrome

Acute Myeloid Leukemia (AML) trials near Montréal, QC, CAN:

A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M)

This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Venetoclax
Drug: Azacitidine

Phase 3

AbbVie
AbbVie

Montreal, Quebec, Canada and 160 other locations

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

will be evaluated in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The main study has ...

Enrolling
Acute Leukemia of Ambiguous Lineage
Mixed Phenotype Acute Leukemia
Drug: Ziftomenib
Drug: Itraconazole

Phase 1, Phase 2

Kura Oncology

Montréal, Quebec, Canada and 55 other locations

Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)

in combination with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults who ar...

Active, not recruiting
Acute Myeloid Leukemia
Drug: Decitabine and Cedazuridine (ASTX727)
Drug: Venetoclax

Phase 1, Phase 2

Taiho Pharma
Taiho Pharma

Montreal, Canada and 33 other locations

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with sel...

Active, not recruiting
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Acute Myeloid Leukemia (AML)
Drug: Zanubrutinib
Drug: PRT2527

Phase 1

Prelude Therapeutics

Montreal, Quebec, Canada and 23 other locations

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent isocitrate dehydrogenase (IDH) inhibitor, in patients with IDH1 and...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Chronic Myelomonocytic Leukemia (CMML)
Drug: Azacitidine
Drug: LY3410738

Phase 1

Lilly
Lilly

Montréal, Quebec, Canada and 36 other locations

Locations recently updated

Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

and Venetoclax in participants with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndro...

Enrolling
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Drug: Azacitidine
Drug: Venetoclax

Phase 1

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Montreal, Quebec, Canada and 14 other locations

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) (cAMeLot-2)

VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutation...

Enrolling
Leukemia, Myeloid, Acute
Drug: Venetoclax (VEN)
Drug: Azacitidine (AZA)

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Montreal, Quebec, Canada and 180 other locations

Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia (ELEVATE)

The purpose of the study is to characterize safety and tolerability of cusatuzumab in combination with various therapies used to treat acute ...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: Azacitidine
Drug: Venetoclax

Phase 1

OncoVerity

Montreal, Quebec, Canada and 22 other locations

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

survival (OS), and disease progression, including progression to acute myeloid leukemia (AML) in transfusion-depe...

Active, not recruiting
Myelodysplastic Syndromes
Drug: Imetelstat Sodium
Drug: Placebo

Phase 2, Phase 3

Geron

Montreal, Quebec, Canada and 126 other locations

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome (Verona)

Some people with MDS have a risk of the disease progressing to acute myeloid leukemia (AML), and a risk of death ...

Active, not recruiting
Myelodysplastic Syndrome (MDS)
Drug: Placebo
Drug: Azacitidine

Phase 3

AbbVie
AbbVie

Montreal, Quebec, Canada and 222 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2025 Veeva Systems